Global pharmaceutical company Eli Lilly (NYSE:LLY) reported in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion.

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Healthcare stocks are generally more resilient in a challenging macro backdrop compared to stocks in other sectors. This is because the need for medicines and medical treatments i ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

A decision is expected in the fourth quarter of 2025.

CVS Health said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Under a new partnership between Caremark ...

Pfizer has not identified one drug to fill gaps, but is betting on specific disease areas, including cancer and obesity, to reverse sales trends. It has invested in oncology drugs, including by ...

Investors will be watching closely whether external partnerships or acquisitions can fill the obesity-drug void and sustain revenue growth as pandemic tailwinds wane. With Q2 results due late July and ...

You can reach Elaine on Signal at elaineywchen.70. Novo Nordisk is expanding its efforts to sell its obesity drug Wegovy directly to patients, striking agreements with telehealth companies ...

Novo Nordisk's diabetes drug Ozempic, which contains the same active ingredient as Wegovy, is already available in Thailand. About 42% of Thailand's adult population is considered obese, and the rate ...

BANGKOK, April 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has launched its hugely popular weight-loss drug Wegovy in Thailand ... and the rate of obesity in school children surged ...